Akebia Therapeutics Inc (AKBA)
followers
·
Follow
| Sector: | HEALTH CARE |
| Industry: | PHARMACEUTICALS |
| SIC: | PHARMACEUTICAL PREPARATIONS |
| CEO: | John P. Butler |
| Employees: | 430 |
| Web site: | akebia.com |
|
245 FIRST STREET, CAMBRIDGE, MA, 02142
617-871-2098
| |
| All 13F Filers | Prior | Change | Hedge Funds 1 | Prior | Change |
|---|
Akebia Therapeutics, Inc. focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients on dialysis.
Please log in first to see chart